Less Effect of Intranasal Than Oral Hormone Therapy on Factors Associated With Venous Thrombosis Risk in Healthy Postmenopausal Women

  title={Less Effect of Intranasal Than Oral Hormone Therapy on Factors Associated With Venous Thrombosis Risk in Healthy Postmenopausal Women},
  author={Majoie Hemelaar and Jan Rosing and Peter Kenemans and M C Thomassen and Didi D.M. Braat and Marius Jan van der Mooren},
  journal={Arteriosclerosis, Thrombosis, and Vascular Biology},
Objective—To compare the effects of intranasal and oral administration of 17&bgr;-estradiol (E2) and norethisterone(acetate) [NET(A)] in healthy postmenopausal women on activated protein C (APC) resistance and other hemostatic parameters associated with venous thrombosis. Methods and Results—In this 2-center, randomized, double-blind, 1-year trial, 90 postmenopausal women (56.6±4.7 years of age) received daily either an intranasal spray with 175 &mgr;g/275 &mgr;g E2/NET (n=47) or 1 mg/0.5 mg… 

Figures and Tables from this paper

Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial

During intranasal E2/NET therapy, changes in the coagulatory and fibrinolytic markers were to some extent less than those observed during oral therapy.

Plasma fibrin clot properties in postmenopausal women: effects of hormone therapy

Estrogen plus progestogen therapy has a minor effect on plasma fibrin properties, but leads to the formation of thicker and more branched fibr in fibers, particularly during oral administration.

Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women.

The CEE associated with MP treatment may reduce AT levels, whereas unopposed CEE or transdermal 17beta-estradiol plus MP does not change AT, and hormonal replacement therapy may increase the risk of thrombosis in women with congenital or acquired thromBophilia.

Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen

Transdermal estrogens combined with norpregnanes may induce APC resistance and activate blood coagulation and provide a biological support to epidemiological data regarding the potential thrombogenic effects of norPregnanes.

Prevention and treatment of venous thromboembolism during HRT: current perspectives

  • H. Rott
  • Medicine, Biology
    International journal of general medicine
  • 2014
Bioidentical hormone therapy via the transdermal route seems to be the safest opportunity for hormone replacement therapy, although large trials for bioidentical hormones therapy are needed.

Effect of two oral doses of 17β‐estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized double‐blind placebo‐controlled study

The aim of the study was to compare the effect of the standard dose of 17β‐estradiol to a lower one on thrombin generation (TG).



Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis: A Randomized, Placebo-Controlled Study in Postmenopausal Women

The increase in resistance to APC was not explained by changes in protein S, protein C, or prothrombin and may contribute to the increased incidence of venous thrombosis in users of hormone replacement therapy.

Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial

The data show that oral, unlike transdermal, estrogen induces APC resistance and activates blood coagulation, and emphasize the importance of the route of estrogen administration.

Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study.

Low-dose oral estradiol therapy was associated with an increase in fibrinolysis and small decreases in procoagulant variables and transdermal therapy had minor effects.

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

Oral estrogen/progesterone replacement therapy may result in coagulation activation and increased fibrinolytic potential, whereas opposed transdermal estrogen appears without any substantial effects on hemostasis.

Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double‐blind, placebo‐controlled trial

It is concluded that HRT diminishes the efficacy by which APC downregulates in‐vitro thrombin formation in a similar fashion to that observed with low‐dose oral contraceptives, but the increase in nAPCsr alone is not sufficient to explain the increased risk of VTE associated with use of HRT.

Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms.

Intranasal administration of 300 microg/d estradiol was at least as effective as oral administration of 2 mg/dEstradiol in alleviating postmenopausal symptoms, with less frequent mastalgia and uterine bleeding and without the metabolic consequences of the first-pass effect.

Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. The Writing Group for the Estradiol Clotting Factors Study.

  • Medicine, Biology
    Thrombosis and haemostasis
  • 1996
Both regimens produce a clinically relevant decrease of fibrinogen levels; the continuous regimen affects also the levels of FVII and inhibitors suggesting that the haemostatic balance is shifted to a more physiological state.

The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.

It is concluded that HRT was associated with early activation of coagulation, which corroborates the finding of an early risk of recurrent VTE and may be explained by reduction in circulating anticoagulants.

Hormone replacement therapy with estradiol and risk of venous thromboembolism--a population-based case-control study.

It is concluded that use of HRT containing estradiol was associated with a threefold increased risk of VTE, but this increased risk was restricted to the first year of use.